Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Chimeric antigen receptor (CAR) T cell therapy is a modern adoptive immunotherapy used to treat patients with relapsed/refractory B cell malignancies. However, clinical results showed that CAR-T cells with suboptimal cytotoxicity and reduced persistence could lead to antigen-positive tumor escape and disease relapse. Interleukin-7 is one of the growth factors related to T cell proliferation and survival. rhIL-7-hyFc, a form of interleukin-7 with longer in vivo serum half-life, was demonstrated to improve CAR-T cell expansion, persistence, and anti-tumor efficacy.
Researchers constructed UCAR-T targeting CD19 or CD33 with T cells from healthy human donors. In vitro culture of UCAR-T with the addition of rhIL-7-hyFc could enhance the CAR-T cell expansion and maintain their polyfunctionality. In a preclinical mouse model experiment, rhIL-7-hyFc promotes expansion, persistence, and anti-tumor efficacy of UCAR-T19 cells in CD19+ tumor-bearing NSG mice and immunocompetent mice. Murine UCAR-T cells were also developed and tested in syngeneic mouse models, and rhIL-7-hyFc improved the survival of CD19-positive tumor-bearing mice with prolonged tumor-free times.
Given the pronounced effect of rhIL-7-hyFc on CAR-T cell expansion and efficacy, rhIL-7-hyFc could also reduce the minimum effective dose of CAR-T cells required for activity. They further elucidated the effects of rhIL-7-hyFc on CAR-T cell phenotype using Single-cell RNA sequencing (scRNA-seq) technology, verifying that rhIL-7-hyFc preferentially expands IL7R positive effector memory CAR-T cells.
Fig.1 Structure of rhIL-7-hyFc and CAR19, and the workflow for UCAR-T production (Kim, 2022)
CAR-T therapy has become a revolution in the area of cancer treatment. Based on up-to-date technology and years of development experience, Creative Biolabs offers one-stop CAR-T therapy development services covering the whole process of CAR-T production. Our high-quality customer service can best fit your technical, program, and budget requirements which can greatly assist your research and preclinical in vitro and in vivo investigation.
CAR is engineered elaborately with highly specific in redirecting T cells targeting malicious cancer cells via a monoclonal antibody fragment. Creative Biolabs offers various CAR design and construction services, including classical CARs, Smart™ CAR, and other special CARs. Our standard pipeline can support rapid and high-quality CAR production.
As CAR-T cell production is largely dependent on CAR gene transfer, genetic engineering of T lymphocytes is one of the most critical steps in generating effective CAR-T cells. Creative Biolabs offers CAR gene packaging and delivery services using versatile methods, including lentivirus transfection, electroporation, and transposon-based transfection.
The development of universal CAR-T from healthy donors could overcome most drawbacks of autologous CAR-T, reducing costs and manufacturing periods. Creative Biolabs offers clients comprehensive solutions to UCAR-T production and insight to overcome the challenges and hurdles in the production process.
Primary mouse CAR-T is an invaluable tool in testing CAR-T cells' response and function after adoptive transfer in various mouse models. Creative Biolabs has a reliable platform in primary murine CAR-T production, equipped with abundant experience in primary mouse T cell engineering and large-scale and long-term culturing of the transduced cell.
To obtain high-quality CAR-T cells, in vitro efficacy test is necessary to verify the solid success of CAR-T construction and superior function. Creative Biolabs offers multiple evaluation services, including CAR expression test, cytokines release test, cytotoxicity test, cell proliferation test, viability test, bio-distribution analysis, and efficacy test.
Preclinical in vivo therapeutic efficacy tests of CAR-T cells in animal models provide valuable information for their later clinical application. Creative Biolabs offers end-to-end workflows, including choosing animal models, designing comprehensive research practices, and handling high-quality in vivo studies.
Creative Biolabs provides various products and kits covering the whole process of immunotherapy development for multiple cancers and antigen targets, such as CAR vector products, CAR cell products, CAR viral particles, CAR animal cells, and so on. Our products are validated by our in-house scientists with high quality and are recognized by global clients.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
